CN106492110A - A kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its application - Google Patents
A kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its application Download PDFInfo
- Publication number
- CN106492110A CN106492110A CN201610980881.7A CN201610980881A CN106492110A CN 106492110 A CN106492110 A CN 106492110A CN 201610980881 A CN201610980881 A CN 201610980881A CN 106492110 A CN106492110 A CN 106492110A
- Authority
- CN
- China
- Prior art keywords
- sobering
- composition
- extract
- liver
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 106
- 210000004185 liver Anatomy 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 16
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 16
- 239000000284 extract Substances 0.000 claims abstract description 142
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 24
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 24
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 6
- 230000002443 hepatoprotective effect Effects 0.000 claims abstract description 6
- 238000007689 inspection Methods 0.000 claims description 23
- 239000007901 soft capsule Substances 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 238000004513 sizing Methods 0.000 claims description 11
- 241000005787 Cistanche Species 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 10
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011812 mixed powder Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims 1
- 239000003595 mist Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 49
- 230000000694 effects Effects 0.000 abstract description 21
- 235000000421 Lepidium meyenii Nutrition 0.000 abstract description 14
- 240000000759 Lepidium meyenii Species 0.000 abstract description 14
- 235000012902 lepidium meyenii Nutrition 0.000 abstract description 14
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 238000013329 compounding Methods 0.000 abstract description 3
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 56
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 231100000753 hepatic injury Toxicity 0.000 description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 14
- 206010067125 Liver injury Diseases 0.000 description 13
- 238000003304 gavage Methods 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000014101 wine Nutrition 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 4
- 102000013563 Acid Phosphatase Human genes 0.000 description 4
- 108010051457 Acid Phosphatase Proteins 0.000 description 4
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000628997 Flos Species 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000004567 concrete Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- WGXUDTHMEITUBO-YFKPBYRVSA-N glutaurine Chemical compound OC(=O)[C@@H](N)CCC(=O)NCCS(O)(=O)=O WGXUDTHMEITUBO-YFKPBYRVSA-N 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002075 anti-alcohol Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- KXMTXZACPVCDMH-UHFFFAOYSA-N methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1CO KXMTXZACPVCDMH-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 101100027969 Caenorhabditis elegans old-1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000009628 lidan Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its application, and the sobering-up composition includes following component：Maca extract, Radix Puerariae extract, Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.Sobering-up composition of the present invention carries out scientific and reasonable compounding through selecting specified raw material, can promote ethanol quick absorption in vivo, decomposition, be conducive to ethanol to take the photograph quickly relieving the effect of alcohol for taker, prevent from being still drank after a night, with preferably liver-protective effect.Sobering-up composition of the present invention can be prepared into relieving alcoholism and protecting the liver preparation or be applied in hepatoprotective functional food.
Description
Technical field
The invention belongs to technical field of Chinese medicines, is related to a kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its answers
With.
Background technology
Liver is the central hub of human body carbohydate metabolism, lipid metabolism and protein metabolism, with dispelling toxicity, detoxicating, secretion gallbladder
The critical functions such as juice.After human body is drunk, ethanol is mainly absorbed by stomach (20%) and duodenum (80%), about 90% ethanol
In liver metabolism.Ethanol has cytotoxicity, makes the lipid peroxidation on liver plasma membrane surface, destroys liver plasma membrane, further sends out
Exhibition is destroyed the structures such as the micro-pipe in hepatocyte and mitochondrion, is made intracellular metabolism disorder, is caused with cell toxicant
Property metabolite produce, so as to cause swelling of liver cell, necrosis.Now, affected by the culture of wine table, many people drank
Degree, beyond the limit of human body alcohol metabolism, so as to cause the damage of liver and the decline of liver function, is constituted to the health of human body
Great threat.
Western medicine play the role of in a short time good, but the treatment of system cannot be carried out to human body and taken good care of, while having
Very big side effect.The essence of health functional food is food, and which contains a certain amount of functional component, can adjust the machine of human body
Can, maintaining healthy prevents certain disease, and safety non-toxic, beneficiaries are wide；With consumer health and safety consciousness gradually
Strengthen, health product have wide market prospect.
CN101716001A discloses a kind of anti-alcohol and liver-protection beverage and production method, by the raw material group of following weight proportion
Into：Radix Puerariae 15%, Herba Artemisiae Scopariae 10%, Flos puerariae lobatae 10%, Fructus Momordicae 10%, tamarind 10%, Fructus Aurantii 10%, product chess piece 10%, Radix Glycyrrhizae
10%th, Pericarpium Citri Reticulatae 15%, pectin 5%, Herba Menthae 3%, raw material through over cleaning, broken, immersion, heating, filtration, clarification, seasoning and adjusting incense,
Lower glue is filtered, sterilization filling makes finished product；There is lidan liver, diuresis, suppress the effect such as gastrointestinal absorption, alcoholic intoxication.
CN101972462A discloses a kind of removing dampness of relieving the effect of alcohol, replenishing QI to invigorate the spleen, the alcohol-neutralize healthy product of promoting the circulation of QI to induce diuresis, by following into
Divide the medicinal plants with ratio：20～60 parts of Japanese raisintree fruit, 20～50 parts of Flos puerariae lobatae (or Radix Puerariae), 10～30 parts of Flos Chrysanthemi, Rhizoma Imperatae 5～
20 parts, 5～20 parts of Semen Phaseoli, 5～10 parts of Fructus Mume, 5～10 parts of Rhizoma Zingiberiss, 5～20 parts of Fructus Crataegi, 5～20 parts of Fructus Hordei Germinatus (parched)；Can also add
Added with：5～10 parts of the Rhizoma Atractylodis Macrocephalae；The formula is integrated use circulation of qi promoting, diuretic, qi-restoratives, stomach function regulating, the method such as be amusing by compatibility, adjusts
Function, antialcoholism action are rapid, and effect is obvious.
In the art, for the exploitation of Traditional-Chinese-medicine-type antialcoholic drugs has a good application prospect, expect to obtain more peaces
Full Chinese medicine composition that is effective, having protection and auxiliary therapeutic action to alcoholic liver injury.
Content of the invention
For the deficiencies in the prior art, it is an object of the invention to provide a kind of sobering-up composition, include its shield of relieving the effect of alcohol
Hepar and its application.The sobering-up composition of the present invention has defencive function and auxiliary therapeutic action, and medicine to alcoholic liver injury
Reason effect is good.
For reaching this goal of the invention, the present invention is employed the following technical solutions：
On the one hand, the present invention provides a kind of sobering-up composition, and the sobering-up composition includes the following raw material extract components：
Maca extract, Radix Puerariae extract, Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
The sobering-up composition of the present invention passes through to extract with Maca extract, Radix Puerariae extract, Rhizoma Curcumae Longae extract and Japanese raisintree fruit
Thing these herbaceous plant are the mutual compatibility of base stock, with playing the role of defencive function and treatment to alcoholic liver injury, solve
The realistic problem that certainly caused hepatic injury crowd increases because drinking.
Maca extract, Radix Puerariae extract, Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract are carried out in the present invention scientific and reasonable
Compounding, each component cooperate in amount ranges, enabling play effect of relieving alcoholism and protecting livers hepatoprotective, lack any of which
One or two kinds of component, or the amount ranges of wherein certain or some components change its relieving alcoholism and protecting the liver that can affect
Effect.
Preferably, raw extract component of the sobering-up composition comprising following weight portion：
In the sobering-up composition of the present invention, the consumption of the Maca extract can be 1 part, 3 parts, 5 parts, 8 parts, 10
Part, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts or 25 parts.
In the sobering-up composition of the present invention, the consumption of the Radix Puerariae extract can be 1 part, 3 parts, 5 parts, 8 parts, 10
Part, 12 parts, 14 parts, 16 parts, 18 parts or 20 parts.
In the sobering-up composition of the present invention, the consumption of the Rhizoma Curcumae Longae extract can be 0.3 part, 0.6 part, 1 part, 3 parts,
5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts or 25 parts.
In the sobering-up composition of the present invention, the consumption of the Japanese raisintree fruit extract can be 0.5 part, 0.8 part, 1 part, 3
Part, 5 parts, 8 parts, 10 parts, 12 parts, 14 parts, 16 parts, 18 parts, 20 parts, 22 parts or 25 parts.
Preferably, raw extract component of the sobering-up composition comprising following weight portion：
It is further preferred that raw extract component of the sobering-up composition comprising following weight portion：
In the present invention, the sobering-up composition also comprising Pericarpium Citri Reticulatae extract, Herba Cistanches extract, Fructus Lycii extract,
Any one in Rhizoma Dioscoreae extract, Fructus Crataegi extract, Fructus Jujubae extract, Radix Glycyrrhizae extract or Poria extract or at least two
Combination.The combination can combining for Pericarpium Citri Reticulatae extract and Herba Cistanches extract, Pericarpium Citri Reticulatae extract and Fructus Lycii extract
Combination, Pericarpium Citri Reticulatae extract combined with Rhizoma Dioscoreae extract, Pericarpium Citri Reticulatae extract and Fructus Crataegi extract, Fructus Jujubae extract and Radix Glycyrrhizae
The combination of extract, Radix Glycyrrhizae extract are combined with Poria extract, Herba Cistanches extract and Fructus Lycii extract and Rhizoma Dioscoreae
The combination of extract, Pericarpium Citri Reticulatae extract are carried with Fructus Lycii extract, Rhizoma Dioscoreae extract, Fructus Crataegi extract, Fructus Jujubae extract, Radix Glycyrrhizae
Take the combination of thing and Poria extract.
Preferably, the sobering-up composition also comprising 1-7 weight portions (such as 1 weight portion, 1.5 weight portions, 2 weight portions, 3
Weight portion, 4 weight portions, 5 weight portions, 6 weight portions or 7 weight portions) Pericarpium Citri Reticulatae extract.
Preferably, the sobering-up composition includes 1-8 weight portions (such as 1 weight portion, 2 weight portions, 3 weight portions, 4 weight
Part, 5 weight portions, 6 weight portions, 7 weight portions or 8 weight portions) Herba Cistanches extract.
Preferably, the sobering-up composition also includes 1-6 weight portions (such as 1 weight portion, 2 weight portions, 3 weight portions, 4 weights
Amount part, 5 weight portions or 6 weight portions) Fructus Lycii extract.
Preferably, the sobering-up composition also includes 1-5 weight portions (such as 1 weight portion, 2 weight portions, 3 weight portions, 4 weights
Amount part or 5 weight portions) Rhizoma Dioscoreae extract.
Preferably, the sobering-up composition also includes 1-7 weight portions (such as 1 weight portion, 2 weight portions, 3 weight portions, 4 weights
Amount part, 5 weight portions, 6 weight portions or 7 weight portions) Fructus Crataegi extract.
Preferably, the sobering-up composition also comprising 1-3 weight portions (such as 1 weight portion, 1.3 weight portions, 1.5 weight portions,
1.8 weight portions, 2 weight portions, 2.5 weight portions, 2.8 weight portions or 3 weight portions) Fructus Jujubae extract.
Preferably, the sobering-up composition also comprising 1-3 weight portions (such as 1 weight portion, 1.3 weight portions, 1.5 weight portions,
1.8 weight portions, 2 weight portions, 2.5 weight portions, 2.8 weight portions or 3 weight portions) Radix Glycyrrhizae extract.
Preferably, the sobering-up composition also includes 1-5 weight portions (such as 1 weight portion, 2 weight portions, 3 weight portions, 4 weights
Amount part or 5 weight portions) Poria extract.
One typical but non-limiting example is：Raw material of the sobering-up composition of the present invention comprising following weight portion
Extract components：
Another typical but non-limiting example is：Original of the sobering-up composition of the present invention comprising following weight portion
Material extract components：
Another typical but non-limiting example is：Original of the sobering-up composition of the present invention comprising following weight portion
Material extract components：
Another typical but non-limiting example is：Original of the sobering-up composition of the present invention comprising following weight portion
Material extract components：
Raw extract component as described above is mixed with and is obtained by the described sobering-up composition of the present invention.
The above raw extract component can be obtained as mentioned above respectively by carrying out individually extracting to corresponding raw material
Extract component.Can also be using the raw material mixing corresponding with component as described above be extracted, can be by wanting
To sobering-up composition formula proportion adjustment raw material consumption obtaining expected sobering-up composition.
Preferably, the process of the mixed extraction is：Raw material mixed powder is broken, soak 1-2h (such as 1h, 1.2h,
1.4h, 1.6h, 1.8h or 2h), extracted；After extraction terminates, vacuum-concentrcted to density is 1.02-1.06g/mL (examples
Such as 1.02g/mL, 1.03g/mL, 1.04g/mL, 1.05g/mL or 1.06g/mL) concentrated solution, obtain the sobering-up composition；
Preferably, the process of the mixed extraction is：Raw material mixed powder is broken, immersion 1-2h (such as 1h, 1.2h, 1.4h,
1.6h, 1.8h or 2h), ultrasonic and circulated extraction is carried out, is extracted after terminating, vacuum-concentrcted to density is 1.02-1.06g/mL
(such as 1.02g/mL, 1.03g/mL, 1.04g/mL, 1.05g/mL or 1.06g/mL) obtains concentrated solution, obtains the combination of relieving the effect of alcohol
Thing；
Preferably, the ultrasonic power during ultrasonic and circulated extraction be 300-2000W (such as 300W, 350W, 400W,
450W, 500W, 600W, 700W, 800W, 900W, 1000W, 1200W, 1500W, 1800W or 2000W), Extracting temperature is 20-30
DEG C (such as 20 DEG C, 22 DEG C, 24 DEG C, 26 DEG C, 28 DEG C or 30 DEG C).
On the other hand, the present invention provides a kind of relieving alcoholism and protecting the liver preparation, and the relieving alcoholism and protecting the liver preparation includes solution as above
Wine compositionss.
Preferably, the dosage form of the relieving alcoholism and protecting the liver preparation can be capsule, tablet, pill, oral liquid, ointment, solidifying
Colloid or aerosol.
In the present invention, the sobering-up composition (concentrated solution for obtaining i.e. produced above) can be directly prepared into orally
Liquid, ointment, gel or aerosol.
Preferably, the sobering-up composition (concentrated solution for obtaining i.e. produced above) drying is prepared plastic into after powder
Wafer, tablet or pill.Preferably, the mode of the drying is spray drying.
Preferably, the capsule is soft capsule.The soft capsule is shaped as ellipse, circle, spherical or water
Drop shape, preferably oval.In the relieving alcoholism and protecting the liver preparation of the present invention, soft capsule can overcome the shortcomings of tablet, traditional piece
After people swallows, through processes such as disintegrate, dissolving, sucking-offs, the time is longer for ingredient for agent, and drug effect loss is higher；Easily simultaneously
Cause the moisture absorption of composition and go bad.Soft capsule dosage form has directly in intestinal absorption after disintegrate, need not dissolving, effectively hide gastric acid
Acid etching and coat of the stomach digestion, absorption, there is content precisely therefore, bioavailability is high, and pharmacological effect is good, and functional materials are steady
Qualitative good, good airproof performance covers the good characteristics such as the bad smell of medicine, taking convenience.
In the present invention, the preparation method of the soft capsule, comprises the following steps：
(1) each component is weighed according to as above formula, be mixed to get component mixture；
(2) by the component mixture through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Soft capsule fill is carried out, the soft capsule is obtained.
On the other hand, the present invention provides application of the sobering-up composition in hepatoprotective functional food.Institute of the present invention
The sobering-up composition that states can be used in hepatoprotective functional food, to play a role in health care to human body with the consumption being suitable for.
Relative to prior art, the invention has the advantages that：
The sobering-up composition of the present invention carries out scientific and reasonable compounding, through zoopery, human body through selecting specified raw material
Test-meal is tested, and is as a result shown that product can promote ethanol quick absorption in vivo, decomposition, is conducive to ethanol to take the photograph the quick of taker
Relieve the effect of alcohol, prevent from being still drank after a night, and there is preferably liver-protective effect.
Description of the drawings
Fig. 1 is the change curve of each treatment group Mouse Weight in embodiment 10；
Fig. 2 is the liver organ coefficient result of variations figure of each treatment group mice determined in embodiment 10.
Fig. 3 is the Serum ALT levels result figure of each treatment group mice determined in embodiment 10；
Fig. 4 is the serum AST levels result figure of each treatment group mice determined in embodiment 10；
Fig. 5 is the serum TG levels result figure of each treatment group mice determined in embodiment 10；
Fig. 6 is the horizontal result figures of serum LDL-c of each treatment group mice determined in embodiment 10；
Fig. 7 is the horizontal result figure of change of serum C HO of each treatment group mice determined in embodiment 10；
Fig. 8 is the level of serum r-GT result figure of each treatment group mice determined in embodiment 10；
Fig. 9 is the horizontal result figure of serum T BIL of each treatment group mice determined in embodiment 10；
Figure 10 is the horizontal result figure of serum ascites albumin gradient of each treatment group mice determined in embodiment 10；
Figure 11 is the horizontal result figures of liver TG of each treatment group mice determined in embodiment 10；
Figure 12 is the horizontal result figure of liver SOD of each treatment group mice determined in embodiment 10；
Figure 13 is the liver MDA level result figure of each treatment group mice determined in embodiment 10；
Figure 14 is the horizontal result figures of liver GST of each treatment group mice determined in embodiment 10；
Figure 15 is the horizontal result figures of liver GSHPX of each treatment group mice determined in embodiment 10；
Figure 16 is the horizontal result figures of liver GSH of each treatment group mice determined in embodiment 10；
Figure 17 is the horizontal result figures of liver CAT of each treatment group mice determined in embodiment 10；
Figure 18 is the horizontal result figure of liver L DH of each treatment group mice determined in embodiment 10.
Specific embodiment
Technical scheme is further illustrated below by specific embodiment.Those skilled in the art should be bright
, the embodiment be only to aid in understand the present invention, be not construed as to the present invention concrete restriction.
Embodiment 1
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
2 parts of 1 part of Maca extract, 3 parts of Radix Puerariae extract, 5 parts of Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
Preparation method is：Obtained respectively carrying as above by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae and Japanese raisintree fruit respectively
Thing is taken, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 2
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
4 parts of 5 parts of Maca extract, 4 parts of Radix Puerariae extract, 1 part of Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
Preparation method is：Obtained respectively carrying as above by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae and Japanese raisintree fruit respectively
Thing is taken, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 3
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
6 parts of 10 parts of Maca extract, 2 parts of Radix Puerariae extract, 8 parts of Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
Preparation method is：Obtained respectively carrying as above by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae and Japanese raisintree fruit respectively
Thing is taken, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 4
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
10 parts of 20 parts of Maca extract, 8 parts of Radix Puerariae extract, 10 parts of Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
Preparation method is：Obtained respectively carrying as above by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae and Japanese raisintree fruit respectively
Thing is taken, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 5
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
20 parts of 25 parts of Maca extract, 1 part of Radix Puerariae extract, 5 parts of Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
Preparation method is：Obtained respectively carrying as above by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae and Japanese raisintree fruit respectively
Thing is taken, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 6
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
3 parts of Maca extract, 2 parts of Radix Puerariae extract, Rhizoma Curcumae Longae extract 2,1 part of Japanese raisintree fruit extract, Herba Cistanches extract 1
Part.
Preparation method is：As above institute is obtained by extracting to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae, Japanese raisintree fruit and Herba Cistanches respectively
The each extract that states, then as above component will carry out being mixed to get sobering-up composition according to formula ratio.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 7
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
4 parts of Maca extract, 3 parts of Radix Puerariae extract, Rhizoma Curcumae Longae extract 1,2 parts of Japanese raisintree fruit extract, 2 parts of Pericarpium Citri Reticulatae extract
With 2 parts of Herba Cistanches extract.
Preparation method is：Extracted using the raw material corresponding with component as described above is mixed, combination of will relieving the effect of alcohol
In thing, raw material (i.e. Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae, Japanese raisintree fruit, the Pericarpium Citri Reticulatae and Herba Cistanches) co-grinding of each component, soaks 2h, enters
Row is extracted；After extraction terminates, concentrated solution of the vacuum-concentrcted to density for 1.02g/mL, concentrated solution is spray-dried to obtain powder
Afterwards, capsule fill is carried out through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step, obtain soft capsule
Agent.
Embodiment 8
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
3 parts of Maca extract, 2 parts of Radix Puerariae extract, 2 parts of Rhizoma Curcumae Longae extract, 4 parts of Japanese raisintree fruit extract, Radix Glycyrrhizae extract 4
3 parts of part, 1 part of Poria extract and Fructus Lycii extract.
Preparation method is：Will be broken for the raw material mixed powder of each component in sobering-up composition, 2h is soaked, ultrasonic circulating is carried out and is carried
Take；Ultrasonic extraction conditions be ultrasonic power 1000W, 25 DEG C of temperature, extract 1.5h；After extraction terminates, vacuum-concentrcted is to close
Spend and concentrated solution is obtained for 1.04g/mL, concentrated solution is spray-dried to obtain powder, through dispensing, pelleting, sizing, drying, inspection ball, bag
Dress, inspection, outer package step carry out capsule fill, obtain soft capsule.
Embodiment 9
In the present embodiment, the sobering-up composition is grouped into by the group of following weight portion：
1 part of Maca extract, 4 parts of Radix Puerariae extract, 1 part of Rhizoma Curcumae Longae extract, 2 parts of Japanese raisintree fruit extract, Radix Glycyrrhizae extract 3
Part, 3 parts of Poria extract, 2 parts of Fructus Lycii extract, 1 part of Rhizoma Dioscoreae extract, 1 part of Fructus Crataegi extract, 1 part of Fructus Jujubae extract, old
1 part of peel extract.
Preparation method is：By to Lepidinm meyenii Walp, Radix Puerariae, Rhizoma Curcumae Longae, Japanese raisintree fruit, Radix Glycyrrhizae, Poria, Fructus Lycii, Rhizoma Dioscoreae, Fructus Crataegi, big
Fructus Jujubae and Pericarpium Citri Reticulatae are extracted respectively obtains each extract as above, then as above component will carry out mixing according to formula ratio
Arrive sobering-up composition.
By sobering-up composition as described above through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Capsule fill is carried out, soft capsule is obtained.
Embodiment 10
In the present embodiment, the sobering-up composition of the preparation of embodiment 1 is investigated for the liver of alcoholic liver injury mice is protected
Shield is acted on, and specific experiment process is as follows：
Alcohol-induced liver injury model in mice is set up by ethanol gavage ICR mice, at the same gavage embodiment 1 prepare relieve the effect of alcohol
Composite preparation (given the test agent E), investigates liver protection of the given the test agent in alcohol-induced liver injury model in mice.In
Experiment puts to death mice after terminating, and determines hematology and liver biochemical and Enzyme target, and Primary Study given the test agent acts on machine
System.
Experiment material：ICR mices totally 60, female, body weight 22-25g, SPF levels Animal House are raised, and Animal House illumination 12 is little
When light and shade replace, temperature 22-26 DEG C, humidity 40-60%.Mouse feeder in IVC cage tools, per 5, cage, mice in experimentation
Free water is ingested.Mice purchase starts formal experiment after Animal House adaptability is raised one week.Laboratory animal operation and place
Reason defers to laboratory animal Ethic review guidelines.
Experimental technique：The foundation of alcohol-induced liver injury model in mice：6-8 week old Female ICR mices, adaptability are raised one week
Afterwards, it is grouped according to body weight at random, is divided into 6 groups, 10 per group, respectively：Normal group, model control group, positive drug are double
Cyclic alcohol group, high, medium and low each three dosage groups of given the test agent E.Daily 2 from the experiment first day：00PM gives 56 degree of Erguotou wines and fills
Stomach mice, daily gavage one-time continuous 31 days, in Erguotou wine, ethanol doses increased with the time, and concrete scheme is ethanol 2g/kg
× 3 days, 4g/kg × 4 day, 6g/kg × 24 day.Normal group mice not gavage Erguotou wine, this group of animal in experimentation
The isopyknic distilled water of gavage.
Evaluating drug effect based on alcohol-induced liver injury model in mice：Given the test agent pharmacodynamic evaluation is little with alcoholic liver injury
Mouse model is set up to be carried out simultaneously.From at 9 points in alcohol-induced liver injury model in mice (gavage Erguotou wine) morning on the same day is begun setting up, give
Given the test agent (sobering-up composition preparation prepared by embodiment 1) gavage mice.Wherein, Normal group and model control group mice
Give distilled water gavage, positive controls gavage bicyclol, dosage 300mg/kg, high, normal, basic three dosage groups of given the test agent point, agent
Amount difference 200mg/kg, 600mg/kg and 1800mg/kg, all mouse stomach volumes are 10mL/kg.
Record Mouse Weight during experiment twice a week, and body weight change data are summarized after experiment terminates.Experimentation
In daily observation mice general state, go out if any the abnormal conditions such as lethargy, the back of a bow, perpendicular hair, obvious weight loss and death
Current record in time.In last time gavage Erguotou wine (administration the 31st day) 4 hours afterwards, blood was taken through mouse orbit, separate blood
Clear and foundation kit specification method measure ALT, AST, ACP, GGT, TBIL, TG, CHO and LDL-c；Put to death after taking blood agglomeration beam
Mice, opens abdominal cavity and separates liver, and determining liver gross weight, and calculate liver organ coefficient carries out statistical analysiss, liver internal organs
Coefficient=liver weight/body weight × 100%.
Liver takes one piece of hepatic tissue formalin fix of lobus sinister after weighing, dye for tissue slice and HE, then it is little to take two
Block hepatic tissue is weighed respectively, after one of homogenate according to kit specification method determine SOD, MDA, CAT, GSHPX, GST,
LDH and GSH, in addition one piece weigh after be homogenized, determine liver TG contents (zoopery packet and dosage regimen are shown in Table 1).
Liver TG content assaying methods：In 1.5mLEP pipes, add 10% liver homogenate to organize 50 μ L, 50 μ L of distilled water, first
200 μ L of alcohol, 400 μ L of chloroform, take 200 μ L of organic faciess liquid and add in new EP pipes after being sufficiently mixed, volatilization.500 μs are used again
L isopropanols fully dissolve.Kit measurement TG content is finally applied.
Table 1
Statistical analysis：Market demand SPSS 22.0 carries out statistical analysiss, compares application One- between the group of measurement data
Way ANOVA, carry out homogeneity of variance analysis and normal distribution-test before comparing, and when variance is neat, application LSD inspections, apply when uneven
Dunnett T3 are checked.
Experimental result：(1) animal ordinary circumstance, body weight and liver organ coefficient change
During experiment initial period ethanol 2g/kg gavage mice, there is not substantially drunk performance, individual mice in all mices
There is excitement, running motion increases in cage.When amount of alcohol increases to 4g/kg, some animals occur drunk, central nerve inhibition
, there is instability of gait, rapid breathing, scratching cage wall, sleep of lying on one's side until righting reflex loss in performance.Amount of alcohol adds to 6g/kg
There is above-mentioned drunk performance in Shi Suoyou mices, and the time continued 30 points to 2 hours.
In this experiment, the middle dose group of given the test agent and high dose group mice each dead are tested when being administered 21 and 22
Only, dissect and have no notable exception.There is not animal dead during remaining 4 groups of mouse experiment.Normal group in experimentation
Mouse Weight gradually increases, and at the end of extremely testing, body weight increases by 28.9% compared with original body mass.Remaining each group in addition to Normal group
Mouse Weight increasess slowly, and after ethanol given low increases to 6g/kg mono- week, in addition to Normal group, remaining each group mice goes out
Existing weight loss.At the end of extremely testing, each medication group Mouse Weight increases 2.2%-3.5% (Fig. 1) compared with original body mass.Additionally, second
It is untidy that hair color dimness also occurs in alcohol gavage group mice, and the more normal control group mice of spirit is poor.
Experiment determines liver organ coefficient after terminating, and as a result shows, compared with Normal group, model control group Mouse Liver
Dirty organ coefficient increased (4.4%vs 4.1%, P=0.109), and test sample each group mouse liver organ coefficient is compared with model
Matched group has lowered (4.2% and 4.3%) but no difference of science of statistics (Fig. 2).
(2) mouse blood index change
Experiment determines mice serum glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST), triglyceride (TG), total after terminating
Cholesterol (CHO), gamma glutamyl transpeptidase (γ-GT), low-density lipoprotein cholesterol (LDL-c), acid phosphatase (ACP)
And total bilirubin (TBIL), as a result show：
1., compared with Normal group, model control group mice serum ALT and AST level significantly raises (difference 83.6U/L
Vs 53.5U/L and 235.3U/L vs 140.9U/L), show liver injury model success.The middle and high dosage group of given the test agent E is little
Mus Serum ALT is significantly reduced (Fig. 3) compared with model group, and tri- dosage of sample E make mice serum AST reduce (Fig. 4).
2., in blood lipids index, compared with Normal group, model control group mice serum TG and LDL-c level significantly increases
Height, the equal showed different TG reduction effect of tri- dosage of sample E, but dose-effect relationship is not significantly (Fig. 5).In LDL-c indexs, sample
Product E significantly reduces mice serum LDL-c levels, and assumes dose-dependant effect (Fig. 6), and all samples are to change of serum C HO level
Affect not substantially (Fig. 7).
3., in other indexs, compared with Normal group mice, model control group mice serum γ-GT levels significantly increase
Height, all given the test agent make mice serum γ-GT levels (i.e. GGT levels in Fig. 8) decrease, but no difference of science of statistics
(Fig. 8).In this experiment, each group mice serum TBIL and ACP level is without significant difference (Fig. 9 and Figure 10).
(3) mouse liver biochemical and zymetology change
Experiment puts to death mice after terminating, and accurately weighs a fritter liver, prepares 10% and is homogenized, and according to kit specification
Dilution variable concentrations are required, hepatic tissue TG, SOD, MDA, CAT, GSHPX, GST, LDH and GSH is determined.As a result show：
1. liver TG：Compared with Normal group, model group mouse liver TG levels significantly increase (41.8mg/g liver
Weight vs 23.7mg/g liver weight), and all given the test agent make liver TG levels reduce in various degree, with
Model control group has compared significance statistical discrepancy (Figure 11).
2. liver SOD and MDA：Compared with Normal group, model control group mouse liver SOD levels are significantly reduced
(305.4U/mgprotvs 396.1U/mgprot).The middle and high dosage of given the test agent E makes liver SOD light horizontally relative to model group
Degree increases, but no difference of science of statistics (Figure 12).Compared with Normal group, model control group mouse liver MDA levels significantly increase
High (2.7nmol/mgprotvs 1.7nmol/mgprot).High dose group sample E reduces liver MDA level, with model group ratio
Compared with significant difference (Figure 13).
3. liver GST, GSHPX, GSH and CAT：Compared with Normal group, model control group mouse liver GST and
GSHPX levels are significantly reduced.Increase mice GST levels after tri- dosage group medications of sample E, wherein low dose group is raised substantially
(Figure 14).After tri- dosage group medications of sample E, mice GSHPX levels slightly increase, but no difference of science of statistics compared with model group
(Figure 15).Although model control group mouse liver GSH and CAT level is significantly reduced compared with Normal group, in this experiment, only
Positive drug bicyclol shows and increases GSH and CAT effects, all given the test agent liver GSH and two indexs of CAT and model comparison
Group compares no difference of science of statistics (Figure 16 and Figure 17).
4. liver L DH：There was no significant difference for liver L DH level to test (including model comparison and Normal group) between each group
(Figure 18).
Above experimental result confirms that the sobering-up composition preparation that embodiment 1 is prepared is protected for alcoholic liver injury has
Shield is acted on and the therapeutical effect with auxiliary, and the pharmacological effect of the sobering-up composition is good, and avirulence, safely and effectively.
Sobering-up composition preparation prepared by embodiment 2-9 is carried out experiment same as in Example 10, embodiment 2-9 is found
The sobering-up composition preparation of preparation equally has significant protective effect and auxiliary to the liver of alcoholic liver injury mice
Therapeutical effect, pharmacological effect are good, safety non-toxic.
Embodiment 11
In this experiment, the soft capsule of the sobering-up composition for being prepared by embodiment 1-9 carries out human feeding trial, respectively
Take to 80 alcohol users, keep the other conditions of per group of experiment identical, the ratio of observation and record with dispelling effects of alcohol, as a result
As shown in table 2.
Table 2
As can be seen from Table 2, by human feeding trial, as a result show that sobering-up composition preparation of the present invention can promote
Enter ethanol quick absorption in vivo, decomposition, be conducive to ethanol to take the photograph quickly relieving the effect of alcohol for taker, prevent from being still drank after a night, which can also be appropriate
Consumption add to food in obtain functional food, to play a part of hepatoprotective.
Applicant states that the present invention illustrates the sobering-up composition of the present invention and relieving the effect of alcohol containing which by above-described embodiment
Liver-care preparations and its application, but the invention is not limited in above-described embodiment, that is, do not mean that the present invention has to rely on above-mentioned reality
Apply example to implement.Person of ordinary skill in the field it will be clearly understood that any improvement in the present invention, to selected by the present invention
The interpolation of the equivalence replacement of raw material and auxiliary element, selection of concrete mode etc., all fall within protection scope of the present invention and disclosure
Within the scope of.
Claims (10)
1. a kind of sobering-up composition, it is characterised in that the sobering-up composition includes the following raw material extract components：Lepidinm meyenii Walp is extracted
Thing, Radix Puerariae extract, Rhizoma Curcumae Longae extract and Japanese raisintree fruit extract.
2. sobering-up composition according to claim 1, it is characterised in that the sobering-up composition is comprising following weight portion
Raw extract component：
3. sobering-up composition according to claim 1 and 2, it is characterised in that the sobering-up composition includes following weight
The raw extract component of part：
Preferably, raw extract component of the sobering-up composition comprising following weight portion：
4. the sobering-up composition according to any one of claim 1-3, it is characterised in that the sobering-up composition also includes
Pericarpium Citri Reticulatae extract, Herba Cistanches extract, Fructus Lycii extract, Rhizoma Dioscoreae extract, Fructus Crataegi extract, Fructus Jujubae extract, Radix Glycyrrhizae carry
Take in thing or Poria extract any one or at least two combination.
5. the sobering-up composition according to any one of claim 1-4, it is characterised in that the sobering-up composition also includes
1-7 weight portion Pericarpium Citri Reticulatae extract；
Preferably, the sobering-up composition also includes 1-8 weight portion Herba Cistanches extracts；
Preferably, the sobering-up composition also includes 1-6 weight portion Fructus Lycii extracts；
Preferably, the sobering-up composition also includes 1-5 weight portion Rhizoma Dioscoreae extracts；
Preferably, the sobering-up composition also includes 1-7 weight portion Fructus Crataegi extracts；
Preferably, the sobering-up composition also includes 1-3 weight portion Fructus Jujubae extracts；
Preferably, the sobering-up composition also includes 1-3 weight portion Radix Glycyrrhizae extracts；
Preferably, the sobering-up composition also includes 1-5 weight portion Poria extracts.
6. the sobering-up composition according to any one of claim 1-5, it is characterised in that the raw extract component is led to
Cross and carry out mixed extraction and obtain after individually being extracted to raw material or mix raw material；
Preferably, the process of the mixed extraction is：Raw material mixed powder is broken, 1-2h is soaked, is extracted；Extraction terminates
Afterwards, vacuum-concentrcted is the concentrated solution of 1.02-1.06g/mL to density, obtains the sobering-up composition；
Preferably, the process of the mixed extraction is：Raw material mixed powder is broken, 1-2h is soaked, ultrasonic and circulated extraction is carried out, is extracted
After end, vacuum-concentrcted obtains concentrated solution to density for 1.02-1.06g/mL, obtains the sobering-up composition；
Preferably, the ultrasonic power during ultrasonic and circulated extraction is 300-2000W, and Extracting temperature is 20-30 DEG C.
7. a kind of relieving alcoholism and protecting the liver preparation, it is characterised in that the relieving alcoholism and protecting the liver preparation includes such as any one of claim 1-6 institute
The sobering-up composition that states；
Preferably, the dosage form of the relieving alcoholism and protecting the liver preparation is capsule, tablet, pill, oral liquid, ointment, gel or gas
Mist agent.
8. relieving alcoholism and protecting the liver preparation according to claim 7, it is characterised in that the sobering-up composition is directly prepared into mouth
Take liquid, ointment, gel or aerosol；
Preferably, the sobering-up composition drying is prepared into capsule, tablet or pill into after powder；
Preferably, the mode of the drying is spray drying.
9. the relieving alcoholism and protecting the liver preparation according to claim 7 or 8, it is characterised in that the capsule is soft capsule；
Preferably, the soft capsule is prepared by the following method and obtains：
(1) each component is weighed according to as above formula, be mixed to get component mixture；
(2) component mixture is carried out through dispensing, pelleting, sizing, drying, inspection ball, packaging, inspection, outer package step
Soft capsule fill, obtains the soft capsule.
10. application of the sobering-up composition according to any one of claim 1-6 in hepatoprotective functional food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980881.7A CN106492110B (en) | 2016-11-08 | 2016-11-08 | Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610980881.7A CN106492110B (en) | 2016-11-08 | 2016-11-08 | Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106492110A true CN106492110A (en) | 2017-03-15 |
| CN106492110B CN106492110B (en) | 2020-08-04 |
Family
ID=58323565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610980881.7A Active CN106492110B (en) | 2016-11-08 | 2016-11-08 | Hangover alleviating composition, hangover alleviating and liver protecting preparation containing same and application of hangover alleviating and liver protecting preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106492110B (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108094795A (en) * | 2018-01-04 | 2018-06-01 | 大连美通生物技术有限公司 | A kind of composite plant activity drink and its preparation method for having the effect of neutralizing the effect of alcoholic drinks of sobering up |
| CN109007808A (en) * | 2018-08-14 | 2018-12-18 | 宝健（北京）生物技术有限公司 | A kind of relieving alcoholism and protecting liver composition and the relieving alcoholism and protecting liver preparation comprising it |
| CN109045273A (en) * | 2018-11-09 | 2018-12-21 | 何蓉蓉 | A kind of Chinese medicinal alcoholism-relieving composition and preparation method thereof |
| CN109123541A (en) * | 2018-09-19 | 2019-01-04 | 深圳太太药业有限公司 | There is the jelly and preparation method thereof of assistant protection function to chemical liver |
| CN110025009A (en) * | 2019-05-17 | 2019-07-19 | 山东润安生物科技有限公司 | A kind of dispelling effects of alcohol and nourishing liver anti-apolexis composition and preparation method thereof |
| CN111893018A (en) * | 2019-05-06 | 2020-11-06 | 青海格拉丹东生物科技开发有限公司 | Maca and Chinese yam based health-care medicinal liquor and preparation method thereof |
| CN112869152A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of anti-alcohol food |
| CN113499416A (en) * | 2021-09-02 | 2021-10-15 | 北京贡源本草生物科技有限公司 | Composition for tonifying liver and kidney and preparation method thereof |
| CN114533792A (en) * | 2022-04-19 | 2022-05-27 | 康源领鲜(山东)海洋科技股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN115068571A (en) * | 2022-04-22 | 2022-09-20 | 山东德升生物工程有限公司 | Traditional Chinese medicine beverage prepared based on fermentation of multiple lactobacilli and preparation method thereof |
| CN116196377A (en) * | 2023-01-06 | 2023-06-02 | 福建省中医药科技开发有限公司 | Composition with liver protection effect and capable of accelerating alcohol metabolism, preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103229999A (en) * | 2013-02-19 | 2013-08-07 | 北京久易生科技有限公司 | Composition has effects of dispelling effect of alcohol and protecting liver and preparation method thereof |
| CN104001135A (en) * | 2014-06-04 | 2014-08-27 | 云南一尧科技开发有限公司 | Healthcare product composition with functions of liver protection and alcoholism relieving |
| CN104524416A (en) * | 2014-12-26 | 2015-04-22 | 王元忠 | Pharmaceutical composition, and use and preparation method of pharmaceutical composition as well as medicine, food and/or health food prepared from pharmaceutical composition |
-
2016
- 2016-11-08 CN CN201610980881.7A patent/CN106492110B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103229999A (en) * | 2013-02-19 | 2013-08-07 | 北京久易生科技有限公司 | Composition has effects of dispelling effect of alcohol and protecting liver and preparation method thereof |
| CN104001135A (en) * | 2014-06-04 | 2014-08-27 | 云南一尧科技开发有限公司 | Healthcare product composition with functions of liver protection and alcoholism relieving |
| CN104524416A (en) * | 2014-12-26 | 2015-04-22 | 王元忠 | Pharmaceutical composition, and use and preparation method of pharmaceutical composition as well as medicine, food and/or health food prepared from pharmaceutical composition |
Non-Patent Citations (2)
| Title |
|---|
| 初玮: "保肝解酒效果显著"九千杯"醒酒糖畅销全国", 《现代营销》 * |
| 尹秋霞，陈英剑，孙晓明，薛炼，武立新: "葛根、枳椇子对大鼠血中乙醇浓度变化的影响", 《山东中医药大学学报》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108094795A (en) * | 2018-01-04 | 2018-06-01 | 大连美通生物技术有限公司 | A kind of composite plant activity drink and its preparation method for having the effect of neutralizing the effect of alcoholic drinks of sobering up |
| CN109007808A (en) * | 2018-08-14 | 2018-12-18 | 宝健（北京）生物技术有限公司 | A kind of relieving alcoholism and protecting liver composition and the relieving alcoholism and protecting liver preparation comprising it |
| CN109123541A (en) * | 2018-09-19 | 2019-01-04 | 深圳太太药业有限公司 | There is the jelly and preparation method thereof of assistant protection function to chemical liver |
| CN109045273A (en) * | 2018-11-09 | 2018-12-21 | 何蓉蓉 | A kind of Chinese medicinal alcoholism-relieving composition and preparation method thereof |
| CN111893018A (en) * | 2019-05-06 | 2020-11-06 | 青海格拉丹东生物科技开发有限公司 | Maca and Chinese yam based health-care medicinal liquor and preparation method thereof |
| CN110025009A (en) * | 2019-05-17 | 2019-07-19 | 山东润安生物科技有限公司 | A kind of dispelling effects of alcohol and nourishing liver anti-apolexis composition and preparation method thereof |
| CN112869152A (en) * | 2019-11-29 | 2021-06-01 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof in preparation of anti-alcohol food |
| CN113499416A (en) * | 2021-09-02 | 2021-10-15 | 北京贡源本草生物科技有限公司 | Composition for tonifying liver and kidney and preparation method thereof |
| CN114533792A (en) * | 2022-04-19 | 2022-05-27 | 康源领鲜(山东)海洋科技股份有限公司 | Composition for dispelling effects of alcohol and protecting liver and preparation method thereof |
| CN115068571A (en) * | 2022-04-22 | 2022-09-20 | 山东德升生物工程有限公司 | Traditional Chinese medicine beverage prepared based on fermentation of multiple lactobacilli and preparation method thereof |
| CN116196377A (en) * | 2023-01-06 | 2023-06-02 | 福建省中医药科技开发有限公司 | Composition with liver protection effect and capable of accelerating alcohol metabolism, preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106492110B (en) | 2020-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106492110A (en) | A kind of sobering-up composition, the relieving alcoholism and protecting the liver preparation comprising which and its application | |
| CN101244110B (en) | Preparation method of Chinese medicine composition with function of releasing fatigue, reinforcing immunity | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| CN105055855B (en) | With Chinese medicine composition for improving sleep, strengthen immunity effect and its preparation method and application | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN106176952A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja and Folium Ilicis | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN106173605A (en) | A kind of Hyperglycemic health care compositions comprising Radix Puerariae and Herba Dendrobii | |
| CN102106890B (en) | Applications and preparation method of saussurea total sesquiterpene lactone | |
| KR20220062386A (en) | Herbal medicine extract composition having depressive mood-regulating action, manufacturing method thereof, and herbal preparation | |
| CN105168887B (en) | Kidney-tonifying and vitality-nourishing soft capsule and preparation process thereof | |
| CN104622993B (en) | Chewable tablet with protective effect on alcoholic liver injuries and preparation method of chewable tablet | |
| CN103735621A (en) | Chinese medicinal composition with blood lipid reducing and immunity enhancing effects | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN107753630A (en) | The pharmaceutical composition and preparation method of a kind for the treatment of of insomnia patients | |
| CN102885919B (en) | A kind of preparation of slimming medicine | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN100361693C (en) | Health restoring agastache dripping pill preparation and its preparing method | |
| CN104605344A (en) | Health food for enhancing immunity and preparation method of health food | |
| CN103893540B (en) | A kind of Chinese medicine composition controlling IGT and preparation method thereof | |
| CN102885918B (en) | A kind of preparation method of weight-reducing Chinese medicinal preparation | |
| CN102885921B (en) | A kind of Chinese medicine composition for losing weight | |
| CN1067270C (en) | Nutritious health care medicine | |
| CN109549193A (en) | A kind of Chinese medicine compound prescription improves the health food and preparation method thereof of sleep | |
| CN107184831A (en) | It is a kind of to treat Chinese medicine composition of hyperlipidemia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |